Pfizer is betting on next-gen cancer drugs to offset slowing demand for COVID vaccines
Pfizer expects cancer drugs developed by Seagen, the biotech company it acquired last year, to generate $10 billion in sales by 2030
Pfizer (PFE) is betting that next-gen cancer therapies will be a key part of its business as demand for COVID vaccines continue to dwindle.